Physician profile
David Everett Easterday
NPI 1700871613
$4,042.23
in general payments reported to CMS, 2019-2025
37 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $335 · 2021: $345 · 2022: $301 · 2023: $622 · 2024: $698 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.71 | 2022-2025 | Vraylar, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $794.62 | 2019-2024 | Qelbree, Qelbree |
| Novo Nordisk INC | $420.73 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $170.31 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $157.69 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $155.02 | 2025 | Fanapt |
| Lilly USA, LLC | $148.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $88.73 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $87.86 | 2020-2025 | Farxiga, Airsupra |
| Nestle Healthcare Nutrition INC. | $86.47 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $77.20 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.02 | 2025 | Caplyta |
| Cranial Technologies, INC | $70.02 | 2024-2025 | Doc Band |
| Amgen INC. | $63.21 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $60.84 | 2022-2025 | Veozah |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.16 | 2024-2025 | Jardiance |
| Allergan, INC. | $54.92 | 2019 | |
| Mylan Specialty L.P. | $52.93 | 2019-2022 | |
| Glaxosmithkline, LLC. | $52.13 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Novartis Pharmaceuticals Corporation | $48.93 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $42.96 | 2022-2025 | Varivax, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $41.26 | 2024 | |
| Lundbeck LLC | $41.19 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $40.96 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $39.23 | 2022-2025 | |
| Viatris Specialty LLC | $38.86 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $35.65 | 2024-2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $32.00 | 2025 | Azmiro, Edarbi |
| Sumitomo Pharma America, INC. | $30.57 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $27.83 | 2024-2025 | Zoryve |
| Sunovion Pharmaceuticals INC. | $26.06 | 2019 | |
| Abbott Laboratories | $24.63 | 2024 | Proclaim |
| Nevro Corp. | $19.91 | 2024 | Senza |
| Alkermes, INC. | $19.61 | 2025 | Lybalvi |
| Axsome Therapeutics, INC. | $17.43 | 2024 | Auvelity |
| Noven Therapeutics, LLC | $15.90 | 2024 | Xelstrym, Secuado |
| Amarin Pharma, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Easterday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.